Sensitivity of imaging for multifocal-multicentric breast carcinoma by A. Bozzini et al.
BioMed CentralBMC Cancer
ssOpen AcceResearch article
Sensitivity of imaging for multifocal-multicentric breast carcinoma
Anna Bozzini*1, Giuseppe Renne2, Lorenza Meneghetti1, Giuseppe Bandi3, 
Gabriela Santos4, Anna Rita Vento4, Simona Menna1, Stefania Andrighetto2, 
Giuseppe Viale2,6, Enrico Cassano1 and Massimo Bellomi5,6
Address: 1Breast Imaging Unit, Department of Radiology, European Institute of Oncology, Via Ripamonti 435 - 20141 Milan, Italy, 2Department 
of Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435 - 20141 Milan, Italy, 3Ospedale Civile degli Infermi 
di Vigevano, C.so Milano 5 - 27029 Vigevano, Italy, 4Department of Senology, European Institute of Oncology, Via Ripamonti 435 - 20141 Milan, 
Italy, 5Department of Radiology, European Institute of Oncology, Via Ripamonti 435 - 20141 Milan, Italy and 6School of Medicine, University of 
Milan, Via Festa del Perdono 7 - 20122 Milan, Italy
Email: Anna Bozzini* - anna.bozzini@ieo.it; Giuseppe Renne - giuseppe.renne@ieo.it; Lorenza Meneghetti - lorenza.meneghetti@ieo.it; 
Giuseppe Bandi - Giuseppe_Bandi@ospedali.pavia.it; Gabriela Santos - gabrielasantos73@hotmail.com; 
Anna Rita Vento - annarita.vento@ieo.it; Simona Menna - simona.menna@ieo.it; Stefania Andrighetto - stefania.andrighetto@ieo.it; 
Giuseppe Viale - giuseppe.viale@ieo.it; Enrico Cassano - enrico.cassano@ieo.it; Massimo Bellomi - massimo.bellomi@ieo.it
* Corresponding author    
Abstract
Background: This retrospective study aims to determine: 1) the sensitivity of preoperative
mammography (Mx) and ultrasound (US), and re-reviewed Mx to detect multifocal multicentric
breast carcinoma (MMBC), defined by pathology on surgical specimens, and 2) to analyze the
characteristics of both detected and undetected foci on Mx and US.
Methods: Three experienced breast radiologists re-reviewed, independently, digital
mammography of 97 women with MMBC pathologically diagnosed on surgical specimens. The
radiologists were informed of all neoplastic foci, and blinded to the original mammograms and US
reports. With regards to Mx, they considered the breast density, number of foci, the Mx
characteristics of the lesions and their BI-RADS classification. For US, they considered size of the
lesions, BI-RADS classification and US pattern and lesion characteristics. According to the
histological size, the lesions were classified as: index cancer, 2nd lesion, 3rd lesion, and 4th lesion.
Any pathologically identified malignant foci not previously described in the original imaging reports,
were defined as undetected or missed lesions. Sensitivity was calculated for Mx, US and re-
reviewed Mx for detecting the presence of the index cancer as well as additional satellite lesions.
Results: Pathological examination revealed 13 multifocal and 84 multicentric cancers with a total
of 303 malignant foci (282 invasive and 21 non invasive). Original Mx and US reports had an overall
sensitivity of 45.5% and 52.9%, respectively. Mx detected 83/97 index cancers with a sensitivity of
85.6%. The number of lesions undetected by original Mx was 165/303. The Mx pattern of breasts
with undetected lesions were: fatty in 3 (1.8%); scattered fibroglandular density in 40 (24.3%),
heterogeneously dense in 91 (55.1%) and dense in 31 (18.8%) cases. In breasts with an almost
entirely fatty pattern, Mx sensitivity was 100%, while in fibroglandular or dense pattern it was
reduced to 45.5%. Re-reviewed Mx detected only 3 additional lesions. The sensitivity of Mx was
affected by the presence of dense breast tissue which obscured lesions or by an incorrect
interpretation of suspicious findings.
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BMC Cancer 2008, 8:275 http://www.biomedcentral.com/1471-2407/8/275US detected 73/80 index cancers (sensitivity of 91.2%), US missed 117 malignant foci with a mean
tumor diameter of 6.5 mm; the sensitivity was 52.9%
Undetected lesions by US were those smallest in size and present in fatty breast or in the presence
of microcalcifications without a visible mass.
US sensitivity was affected by the presence of fatty tissue or by the extent of calcification.
Conclusion: Mx missed MMBC malignant foci more often in dense or fibroglandular breasts. US
missed small lesions in mainly fatty breasts or when there were only microcalcifications. The
combined sensitivity of both techniques to assess MMBC was 58%. We suggest larger studies on
multimodality imaging.
Background
Multifocal-multicentric tumors of the breast (MMBC) are
defined by the presence of two or more physically separate
neoplasms in the same breast. Pathologists define multi-
ple, simultaneous primary lesions when there are two or
more foci of tumors without intervening neoplastic tissue
[1,2]. They are defined as multifocal when only one breast
quadrant is involved and multicentric when two or more
quadrants are involved [1,3]. An exact "radiological defi-
nition" does not exist, but tumors are usually considered
as multifocal when the distance is less than or equal to 5
cm and multicentric when the distance is more than 5 cm
between lesions [4]. Given the lack of anatomically dis-
tinct borders between the breast quadrants, and the diffi-
culty in radiologically evaluating the actual distance
between lesions, for the purpose of the current investiga-
tion multifocal and multicentric tumors were collectively
identified as MMBC.
The estimated prevalence of MMBC is between 4 and 65%
of all breast carcinomas; this variability is mainly due to
lack of standardization in the gross examination and sam-
pling of breast specimens [5,6]; furthermore, sampling
may be limited to the areas with suspicious macroscopic
findings, or may be extensively performed, sometimes
using whole mount sections.
Several reports have shown that the sensitivity of mam-
mography (Mx) and ultrasound (US) for detecting multi-
ple malignant foci is about 50% [4,7-14], while the
sensitivity of Magnetic Resonance Imaging (MRI) is
higher in detecting MMBC, reaching 94–99% sensitivity
for invasive ductal carcinoma (IDC) and 50–80% for duc-
tal intraepithelial neoplasia (DIN) [10,15].
This retrospective study aims at assessing the sensitivity of
preoperative Mx and US and of re-reviewed mammo-
grams to detect MMBC identified at pathological exami-
nation of surgical specimens, as well as analyzing the
characteristics of both detected and undetected foci on Mx
and US and the sensitivity of both methods.
Methods
From October 2000 to October 2004, 1129 (14.5%) of
7769 breast cancers treated at the European Institute of
Oncology in Milan were diagnosed as MMBC.
Among these, we selected 97 patients who undertoke pre-
operative digital imaging Mx and for whom the complete
series of images were retrievable. Eighty of them (82%)
were also examined by US. The median age of the patients
with MMBC was 48 years (range 26–78 years). Sixteen
(17%) patients were treated pre-operatively with neo-
adjuvant chemotherapy and presurgical Mx and US were
evaluated.
Fifty-six (58%) patients underwent mastectomy and 41
(42%) breast-conserving surgery. For macroscopic sam-
pling we used the reference standard of serial 5-mm slic-
ing of the surgical specimen (lumpectomy or
mastectomy) following Egan's methods [16]. Pathological
evaluation was performed on tumor blocks sampled from
any suspicious areas. The histopathologic examination of
the specimens had been performed independently by the
2 breast pathologists who are co-authors of this paper.
Tumors were defined as MMBC when at least 5 mm of
normal tissue was interposed between the two lesions
[17]. For all identified neoplastic lesions, the histological
features, including size, tumor type, grade, presence of
intraepithelial neoplasia (including lobular intraepithe-
lial neoplasia [LIN] which has disagreeing pathologic
interpretations especially in regard to multifocal lesions)
were recorded and correlated with the original Mx report.
The pathologically identified malignant foci not previ-
ously described in the original imaging report, were
defined as undetected lesions. All lesions were recorded
and ranked according to size: "index cancer" designated as
the one seen at Mx, which prompted the operation, fol-
lowed by 2nd lesion, 3rd lesion, and 4th lesion. The mean
histologic tumor size was measured for the index cancer as
well as for each additional lesion. The mean distance, tak-
ing into consideration, the longest and the shortest dis-Page 2 of 9
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expert radiologists, with more than 5 years experience in
breast imaging, re-reviewed independently all the mam-
mograms, after being informed of the histopathological
findings. Mx had been performed with digital equipment
(GE SENOGRAPHE 2000 D, Milwaukee, WI, USA). Rou-
tine mediolateral, oblique and craniocaudal mammo-
grams were obtained in all patients, and whenever
required by the radiologist, additional spot-compression
magnification and true-lateral images were performed, to
better study the suspicious findings and the extent of dis-
ease. Each breast was classified into one of the four fol-
lowing groups according to its density as defined by the
BI-RADS lexicon 1) breast with the density of fat, 2) fatty
breast with scattered fibroglandular densities, 3) heteroge-
neously dense breast, 4) dense breast [18-27]. We evalu-
ated the number of lesions, their Mx features and
classified the lesions with respect to: microcalcifications
(elements, distribution, and number), mass lesions
(shape, margin, and density), microcalcifications in a
mass, architectural distortions and focal asymmetry of
glandular tissue. The largest pathological diameter was
used as the lesion size.
The microcalcifications were further classified according
to the BI-RADS lexicon: benign or amorphous, scattered,
diffuse, in multiple clusters (BI-RADS<= 3); amorphous,
pleomorphic, heterogeneous, with distribution in clus-
ters, segmental or regional (BI-RADS 4); allomorphic, het-
erogeneous, linear, branching with linear or segmental
distribution (BI-RADS 5).
Based on the description of mass lesions, the lesions were
classified according to BI-RADS: round, oval with circum-
scribed margins and equal or low density (BI-RADS 3);
lobular, irregular with microlobulated, obscured, indis-
tinct margins and equal or rather high density (BI-RADS
4); irregular with indistinct, spiculated margins and high
density (BI-RADS 5). "Architectural distortion": the nor-
mal architecture is distorted with no definite mass visible
(BI-RADS 4–5). Focal asymmetric breast tissues were clas-
sified as BI-RADS 4 [27,28].
Eighty out of 97 (82.5%) patients were also examined by
US. US was performed using a 10–14-MHz linear-array
probe (Esaote Technos, Genoa, IT). Suspicious areas were
also scanned by radial and antiradial orientation with and
without compression. US assessment was based on
reports and the images were re-reviewed by the same three
expert radiologists in breast imaging. All the US reports
were appropriate to the corresponding images. In the US
reports relating to images, the following features were
considered: echo pattern, shape, boundary and margin of
the lesions (Table 1). The index cancer and subsequent
lesions were evaluated and descriptions classified accord-
ing to BI-RADS: oval, isoechoic with circumscribed mar-
gins, sometimes having an echogenic halo, posterior
acoustic enhancement or none (BI-RADS 3); irregular,
hypoechoic with abrupt interface and without posterior
acoustic shadowing (BI-RADS 4–5); the same sono-
graphic assessment but with the presence of microcalcifi-
cation in the lesion (BI-RADS 5). All lesions detected by
Mx and US were classified according to BI-RADS lexicon:
BI-RADS code 5: highly suggestive of malignancy; BI-
RADS code 4: suspicious for malignancy; BI-RADS code 3:
probably benign; BI-RADS code 2 benign; BI-RADS code
1 negative [18,27]. Lesions categorized as BI-RADS 1, 2
and 3 were considered missed in the sensitivity calcula-
tions.
Sensitivity was calculated for Mx and Us to detect the
index and additional cancers: true positive\true positive +
false negative.
The imaging characteristics of the lesions were analyzed
together with the specific sensitivity. A case report form
(CRF), composed of three sections was prepared for
recording data of the lesions. The first CRF section
included the pathological findings, the second the data
from the original imaging reports and the last section
included the findings from mammogram re-review and
the subsequent observations of the radiologist who re-
reviewed the cases. In order to perform statistical analysis
and calculate sensitivity, the data were also recorded in a
customized digital data base (Access 97, Microsoft®, Red-
mond, WA, USA). Statistical analysis was carried out to
determine whether the detection rate of MMBC at Mx and
at US was related to the size of the index cancer or to
breast density.
Table 1: Breast density for US lesions.
Φ Foci  
pathology
detected
Det 
US
UD 
US
Dense 
Breast
Heterogeneous 
Dense Breast
Fatty 
breast
Fatty with  
fibroglandular
tissue...
1 23,8 mm(2–70) 80 73 7 2 1 3 1
2 8,7 mm(0,1–39) 80 35 45 8 3 18 16
3 6,6 mm(0,1–20) 46 15 31 4 2 15 10
4 6,6 mm(0,1–39) 45 10 35 9 5 17 4Page 3 of 9
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Pathological examination of the 97 histopathologic spec-
imens revealed 303 neoplastic foci (282 invasive and 21
intra-epithelial). The mean number of foci per patient was
3. Neoplastic lesions were: invasive ductal carcinoma
NOS in 215 (71%) cases, invasive lobular carcinoma in
57 (19%) cases, ductal intraepithelial neoplasia in 16
(5%) cases, lobular intraepithelial neoplasia (LIN2) in 5
(1.6%) cases, invasive micropapillary and tubular carci-
noma in 10 (3.2%) cases (Table 2).
The mean tumor size was 25 mm for the index cancer
(range: 2 – 77), 9 mm for the second lesion (range 8–39
mm), and 6.6 mm (range 1–25 mm) for the additional
lesions (Table 3). The mean distance, between neoplastic
foci was 10 mm, 80 mm and 5 mm (Table 4). Mx detected
83/97 index cancers (85.6% sensitivity), 38/97 2nd
lesions (39.2% sensitivity), 11/55 3rd lesions (21.8% sen-
sitivity), 3/33 4th lesions (12.1% sensitivity), 3/23 further
lesions (13.0% sensitivity).
For index cancers, the evaluation of Mx BI-RADS was 14
(15%) BI-RADS 1; 10 (10%) BI-RADS 3; 30 (31%) BI-
RADS 4; 43 (45%) BI-RADS 5. Mx missed 165 malignant
foci with a mean size of 7.6 mm. Overall sensitivity for Mx
was 45.5% (138/303) (Table 5).
The patterns of lesions defined at Mx re-review were as fol-
lows: 32 microcalcifications, 51 mass lesions, 46 micro-
calcifications in masses, 8 distortions and 4 glandular
asymmetries (Table 6). The histological type of carcino-
mas undetected by Mx was invasive ductal carcinoma
NOS in 105 (63.6%) cases, invasive lobular carcinoma in
36 (21.8%) cases, ductal intraepithelial neoplasia in 12
(7.2%) cases, lobular intraepithelial neoplasm in 5
(3.03%) cases, and invasive micropapillary and tubular
carcinoma in the 7 (4.2%) remaining cases (Table 2).
The breast pattern of those undetected Mx lesions was:
fatty breast in 3 (1.8%) cases, fatty breast with scattered
density in 40 (24.3%) cases, heterogeneous dense breast
in 91 (55.1%) cases, and dense breast in 31 (18.8%) cases
(Table 3).
In our series, Mx sensitivity of breasts with an almost
entirely fatty pattern was 100%, while in fibroglandular or
dense pattern, sensitivity is reduced to 46% (Table 7).
Re-review of mammograms detected 3 additional lesions
not reported at the original examination: one index cancer
and two 4th lesions (Table 5). These lesions were defined
as masses with margins obscured by superimposing adja-
cent tissue which was isodense with fine amorphous cal-
cifications (BI-RADS 4). The 3 additional lesions were in
heterogeneous dense breasts.
US detected abnormal imaging as solid lesions with ill
defined or irregular borders, non calcified lesions with
posterior acoustic shadowing, solid intracistic or intraduc-
tal lesions.
We based a patient's final imaging diagnosis on the com-
bination of mammographic and sonographic findings.
US detected 73/80 index cancers (91.2% sensitivity), 35/
80 2nd lesions (43.8% sensitivity), 16/46 3rd lesions
(34.8% sensitivity), 10/45 further lesions (22.2% sensitiv-
ity). For index cancers, the evaluation of US BI-RADS were
9 (11%) BI-RADS 1; 2 (3 %) BI-RADS 3; 28 (35) BI-RADS
4; 41 (51%) BI-RADS 5 [27]. US missed 117 malignant
foci with a mean tumor diameter of 6.5 mm. The sensitiv-
ity was 52.9% (133/251) (Table 8).
US missed the smallest lesions that were close in proxim-
ity to the largest lesion in fatty breast or when there were
microcalcifications without a US visible lesion mass
(Table 4, 9). Clusters of microcalcifications or some linear
or segmental microcalcifications are not visible at US for
the lack of a lesion mass.
The re-review gave the same results only based on the
reports corresponding to the US images.
Table 2: Sensitivity of mammography and number of lesions detected and undetected at the original Mx report according to the 
histological type: IDC = Invasive ductal carcinoma; ILC = invasive lobular carcinoma; other IC = invasive carcinoma of special type; 
DIN = ductal intraepithelial neoplasia; LIN = lobular intra-epithelial neoplasia;
N. Mx detected Mx Undetected Sensitivity (%)
IDC 215 110 105 51.2
ILC 57 21 36 36.8
other IC 10 3 7 30
DIN 16 4 12 25
LIN 5 // 5 0.0
Tot 303 138 165 45.5Page 4 of 9
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The accurate definition of multifocal and multicentric
breast carcinoma according to the distribution of the neo-
plastic foci within the same or different quadrants of the
affected breast is hampered by the lack of anatomically
defined borders between the quadrants and it gives no
precise information about the intervening distance. The
different definitions may be responsible for the wide
range of prevalence of MMBC reported in literature [6].
The current TNM classification criteria (AJCC/UICC),
refers to diameter of the largest lesion mass for the T clas-
sification of multifocal-multicentric carcinomas, thus
underestimating the total tumor volume and understag-
ing these tumors [14,19]. However, if the sum of the
diameters of all tumor masses is taken into account, then
the metastatic pattern of MMBC does not significantly dif-
fer from that of unifocal tumors of the same size of the
sum [21,22]. Moreover, Brenin and Morrow demon-
strated a higher incidence of axillary lymph node metas-
tases in MMBC than unifocal tumors of the same pT class
[20]. For these reasons we think that any neoplastic foci
should be measured to verify Fish's statement: "mean size
of unifocal tumors was smaller than multifocal cases
when an aggregate measurement of foci was utilized"
[24].
Accurate pre-operative information about the occurrence,
size and location of multifocal lesions is a prerequisite for
a proper breast conserving surgical management.
Mx has been established as the fundamental breast imag-
ing modality.
In our study the most frequent Mx pattern was character-
ized by heterogeneous dense breast (encountered in
56.7% of the patients), while a fatty pattern was observed
in only 2.1%. In the literature Mx is most sensitive for
detection of index cancer in fatty breasts, while the sensi-
tivity decreases in breasts with fibroglandular or dense
patterns.
In our series, sensitivity of Mx was 85.6% in the detection
of the index cancer, but reduced to 45.5% in the detection
of all the neoplastic foci. It is also important to emphasize
that the re-review of mammograms did not significantly
increase the overall sensitivity in detecting MMBC, con-
firming that, while the sensitivity for identifying the index
cancer is high, it decreases for the smaller additional foci.
This indicates that in dense breasts the smallest foci can-
not be distinguished [25].
The re-review of mammograms detected 3 additional
lesions: one index cancer and two 4th lesions, described as
masses with margins obscured by adjacent tissue that was
isodense with fine amorphous calcifications.
Following prior definitions in the literature, lesion pat-
terns were defined at Mx re-review as: 32 microcalcifica-
tions, 46 microcalcifications in nodules, 51 masses, 8
distortions and 4 others, confirming that even small clus-
ters of microcalcifications are well detected in dense
breasts. The mean diameter of the pathology rank was 2
and 6.3 mm, for the index cancer and ultimate satellite
lesion, respectively (Table 5). The mean size of the lesions
undetected by Mx re-review is 11 and 2.5 mm, for the
index cancer and ultimate satellite lesion, respectively
(Table 9).
Table 3: Number of undetected lesions at the original Mx report according to breast pattern and lesion rank (1° = index cancer)
Lesion rank mean diameter 
and range
Total number of 
UD Mx lesions
Dense Breast (%) Heterogeneous 
Dense Breast (%)
Fatty Breast with 
scattered 
Fibroglandular 
densities (%)
Breast with the 
density of fat (%)
index lesion 25 mm (2–77) 14 3 (21.4) 8 (57.2) 3 (21.4) 0 (0.0)
2nd 9 mm (0.1–39) 61 12 (19.7) 31 (50.8) 17 (27.9) 1 (1.6)
3rd 6.9 mm (0.1–20) 44 6 (13.6) 25 (56.8) 12 (27.3) 1 (2.3)
4th 6.8 mm (0.1–39) 29 6 (20.7) 17 (58.6) 5 (17.2) 1 (3.5)
≥ 5th 6.3 mm (0.1–25) 17 4 (23.5) 10 (58.8) 3 (17.7) 0 (0.0)
Total 165 31 (18.8) 91 (55.1) 40 (24.3) 3 (1.8)
(UD Mx = Lesions undetected at mammography).
Table 4: Range of the distance between each of the lesions and all of the other satellite lesions measured at histopathology.
Range of Histological distance Intra lesion (mm) Index lesion 2nd 3rd ≥ 4th
Range 5 – 80 5 – 80 5 – 25 5Page 5 of 9
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Mx include: above all, dense parenchyma obscuring
masses particularly in the absence of microcalcifications
followed by technical errors and incorrect interpretation
of suspicious findings [29,30]. These results are in line
with the conclusions of Mendelson et al., who evaluated
breast density as a predictor of mammographic lesion
detection [31].
US is a useful complementary method in detecting addi-
tional tumors that escaped Mx detection [13,14]. US may
detect small masses in glandular tissue but is not as help-
ful in fatty tissue or in the characterization of morphology
or the extent of calcifications [29,31].
In our series dealing with a majority of dense breasts, the
global sensitivity of US is 52.9%, being 91.2% for the
index lesion. The use of US in addition to Mx, increases
global sensitivity to 58% in assessing multifocality (Table
10).
According to the literature, mammographic-sonographic
sensitivity does not exceed 60–63% [30], thus we can then
speculate that undetected malignant foci in the remaining
breast tissue after breast-conserving surgery should not
affect the overall survival rates of the patients, as indicated
by the randomized trials comparing mastectomy with
conservative surgery [32]. Post-operative radiotherapy has
a major role in reducing the risk of ipsilateral tumor recur-
rence in conservatively treated patients [33]. These argu-
ments could question the need for an accurate pre-
operative diagnosis of MMBC using MRI to detect all sat-
ellite foci around the main lesion to exactly determine the
impact of imaging on the recurrence rate and on the over-
all survival of patients with breast cancer: ad hoc clinical
trials should be designed to answer this question.
Conclusion
Mx and US missed 165 and 118 of 303 malignant foci,
respectively. Mx missed small malignant foci of MMBC
especially in dense or fibroglandular breasts. Re-review of
the Mx detected only a few additional lesions and did not
significantly increase the sensitivity of the examination.
US missed small lesions, close to the largest lesion, in fatty
breasts. US also missed cancers presenting as Mx microcal-
Table 5: Number of lesions detected by Mx at the original report and at re-review of mammograms with their BI-RADS (Mx) class 
according to re-review rank.
Lesion 
rank
Number of   
lesions
detected by
Pathology
Number of  
lesions 
detected by
original MX
Mx BIRADS Number of 
lesion
detected at
re-revision
Sensitivity 
%
Mean  
diameter at
Pathology 
1 2 3 4 5
Index lesion 97 83 1 0 1 3 4 84 85.6 25
2nd 97 38 4 1 0 0 3 38 39.2 9
3rd 55 11 5 0 5 1 1 12 20.0 6.9
4th 33 3 9 0 1 5 7 5 9.1 6.8
>5th 23 3 4 - 0 6 4 3 13.0 6.3
6th 4 - 2 1
7th 3 1 2
8th 0
9th 2
0
Tot 303 138 141 45.5 //
Table 6: Characteristics of the lesions seen at re-review of the mammograms according to their rank.
Lesions Index lesion 2nd 3rd 4th 5th ALL
Microcalcifications 18 9 3 1 1 32
Mass feature 30 16 2 2 1 51
Microcalcifications+Mass 28 15 3 - - 46
Distortion 5 2 1 - - 8
Other 3 1 - - - 4
total 84 43(38) 9(12) 3(5) 2(3) 141Page 6 of 9
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Table 7: Pattern and sensitivity of mammography in the index lesion related to their BI-RADS class.
BIRADS
ALL 1 %* 3 %* 4 %* 5 %*
Entirely fatt 2 - - - - 1 1.0 1 1.0
Scattered fibroglandular densities 26 4 4.1 3 3.1 10 10.3 9 9.3
Heterogeneously dense 55 9 9.3 4 4.1 16 16.5 26 26.8
Extremely dense 14 4 4.1 1 1.0 3 3.1 6 6.3
97 17 8 30 42
In breast with an almost entirely fatty pattern, the sensitivity of Mx was 100% while in dense breast sensitivity was 40.5%.
Table 8: Sensitivity of US and number of lesions detected by US according to lesion rank and size with their BI-RADS code and US 
pattern: hypo-echoic (hypo); iso-echoic (iso)
Lesion rank Mean histologic 
diameter
Total number of 
lesions detected by 
pathologists
Number of lesions 
detected by US
BIRADS US Hypo Iso Sensitivity (%)
1 2 3 4 5
Index lesion 25 80 73 7 - 4 28 41 71 2 91.2
2nd 9 80 35 45 - 3 16 16 33 2 43.8
3rd 6.9 46 15 31 - 1 7 7 15 - 32.6
≥ 4th 6.5 45 10 35 - 2 4 4 8 2 22.2
Tot // 251 133 52.9
Table 9: Size (mean, median and range in millimeters) and rank of lesions undetected by US, Mx and re-reviewed mammograms
Lesion rank Undetected by US Undetected by Mx Undetected by re-Rev Mx
Index lesion 23.8 15.8 14.7
15 11.5 11
2 – 70 3 – 52 3 – 52
2nd 8.8 8.4 8.4
6 6 6.4
0.1 – 39 0.1 – 39 0.1 – 39
3rd 6.6 6.6 6.1
5 5 4.5
0.1 – 20 0.1 – 20 0.1 – 20
4th 6.2 6.8 6.8
4 4 4
0.2 – 39 0.1 – 39 0.1 – 39
≥ 5th 6.3 5.7 5.7
3 2.5 2.5
0.1 – 25 0.1 – 25 0.1 – 25
BMC Cancer 2008, 8:275 http://www.biomedcentral.com/1471-2407/8/275cifications without a mass. The combined sensitivity of
both techniques was 58%.
The need for an accurate pre-operative assessment of
patients with MMBC is currently debated, due to the
uncertain effect of multifocality or multicentricity on the
recurrence rate and on the overall survival of patients
treated with breast-conserving surgery and post-operative
radiotherapy.
In summary, whole breast sonography is the first-line
complementary imaging modality to mammography in
the preoperative examination of women. Considering
that the global sensitivity for assessing multifocality is
58%, we suggest more and larger studies on multimodal-
ity imaging (US and Mx and then MRI in comparison)
and long term observation periods to determine the influ-
ence on the incidence of recurrence and on the overall
prognosis of patients with breast cancer.
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